登录新浪财经APP 搜索【信披】查看更多考评等级 来源：环球网 【环球网综合报道】2026年1月16日，上海证券交易所对浙江海正药业股份有限公司（简称：海正药 业）及6名相关责任人进行了通报批评，原因是该公司在2021年至2024年的年度报告中存在财务信息不 真实、不准确的问题。与此同时，浙江证监局也向海正药业出具了警示函，并将相关责任人记入证券期 货市场诚信档案。 上海证券交易所《纪律处分决定书》指出，经查明，海正药业于2025年8月26日披露《关于前期会计差 错更正的公告》，对2021—2024年年度报告的部分财务数据进行更正，其中涉及营业收入、营业成本以 及投资收益等科目。上述事项反映出海正药业此前披露的相关报告财务信息不真实、不准确。 《关于前期会计差错更正的公告》显示，2021—2023年，海正药业全资子公司浙江省医药工业有限公司 （以下简称"省医药公司"）部分原料贸易业务缺乏充分的商业实质及商业合理性，不满足收入确定的条 件，相应形成的重要前期差错更正涉及合计调减2021—2023年合并财务报表营业收入94882.64万元，调 减营业成本93002.88万元，调增投资收益1879.77万元；调增2 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has been issued warning letters due to inaccurate financial information, affecting its two former chairmen and several executives [1][2]. Group 1: Regulatory Actions - The China Securities Regulatory Commission (CSRC) Zhejiang Bureau issued warning letters to the company and its executives for violations of the Information Disclosure Management Measures [2]. - The company and its executives, including former chairmen Jiang Guoping and Shen Xinghu, are now recorded in the integrity archives of the securities and futures market [2]. Group 2: Financial Corrections - The company announced corrections to its financial data for the years 2021-2024, which included adjustments to operating income, operating costs, and investment income [1][4]. - The total adjustments included a reduction of operating income by 948.83 million yuan and a reduction of operating costs by 930.03 million yuan for the years 2021-2023 [4]. Group 3: Company Background - Zhejiang Haizheng Pharmaceutical is a state-owned enterprise based in Taizhou, Zhejiang, with a diverse portfolio in chemical, biological, animal, and traditional Chinese medicine [2]. - The company has been involved in financial discrepancies for four consecutive years, linked to its subsidiary Zhejiang Pharmaceutical Co., Ltd. [3]. Group 4: Business Restructuring - In December 2025, the company announced the sale of its subsidiary Zhejiang Pharmaceutical to optimize its business structure and focus on core pharmaceutical areas [4]. - The sale was confirmed with Guangzhou Pharmaceutical Co., Ltd. for a transaction price of 505 million yuan [4].